CoreMedic AG

CoreMedic AG is a Swiss company specializing in innovative cardiology solutions, particularly focused on treating mitral valve regurgitation through its advanced product, ChordArt. Founded in 2012 in Bern, Switzerland, CoreMedic AG develops solutions for mitral valve regurgitation, leveraging its flagship product, ChordArt. The company has undergone strategic focus in its operations but has maintained a clear mission. The co-founders, Dipling Bogenschuetz and Thomas Bauer, have extensive backgrounds in medical device development.

CoreMedic has completed one funding round, securing venture funding in July 2017. CoreMedic GmbH specializes in the development of innovative cardiology solutions, primarily addressing mitral valve regurgitation through its flagship product, ChordArt. This system utilizes a minimally invasive operational procedure to replace mitral chords, launched after successful human trials in 2018. ChordArt targets healthcare facilities across Europe, particularly in Germany and neighboring countries, enhancing patient outcomes in severe MR cases.

CoreMedic GmbH generates revenue through the sales of its ChordArt TMVr system, which is positioned as a premium solution in the cardiology market. The company engages in B2B transactions with hospitals, cardiac specialists, and medical device distributors. Clients typically enter direct purchasing agreements for the ChordArt system, including bulk orders and partnerships for product support and training, tailored to healthcare facilities' needs. CoreMedic AG plans to enhance its product line with new offerings targeting mitral valve solutions, with anticipated releases following further research and development.

The company aims to expand its market reach into additional European countries by 2025. The venture funding raised in July 2017 will support these initiatives, facilitating product development and market expansion.